Pulnovo Medical recently raised an undisclosed amount totaling millions of dollars in investment funding to support clinical trials and…
Articles by Forest Ray PhD
An investigational therapy called R-107 completely stopped the progression of pulmonary arterial hypertension (PAH) in a rat model…
The U.S. Food and Drug Administration (FDA) has granted priority review status to the application seeking approval of Tyvaso DPI…
Scientists have created a new “cellular blueprint” of healthy lung cells that provides a reference against which tissue from lungs…
People with pulmonary hypertension (PH) are invited to apply for $500 micro-grants offered by Team PHenomenal Hope to help cover…
On May 5, the Pulmonary Hypertension Association (PHA) will join more than 80 organizations around the world in marking…
The Pulmonary Hypertension Association (PHA) has published a guide to educate healthcare providers and parents on persistent pulmonary…
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
Tenax Therapeutics has acquired PH Precision Med (PHPM), a private biotech focused on developing imatinib as a treatment…
The prolargin protein may serve as a biomarker for pulmonary arterial hypertension (PAH), allowing for earlier diagnosis and differentiating…
Dialing up the activity of a gene called IRF7Â may reduce pulmonary artery thickening, lower blood pressure, and ease…
Combined with sildenafil, the potential therapy NTP42 eased symptoms of pulmonary arterial hypertension (PAH) in a rat model…